Top

Published in:

01-07-2013 | Original Article

Influence of the in situ component in 389 infiltrating ductal breast carcinomas

Authors: Pau Carabias-Meseguer, Ignacio Zapardiel, Maite Cusidó-Gimferrer, Sonia Godoy-Tundidor, Francesc Tresserra-Casas, Ignacio Rodriguez-García, Rafael Fábregas-Xauradó, Jordi Xercavins-Montosa

Published in: Breast Cancer | Issue 3/2013

Abstract

Background

Our aim was to evaluate and compare lymph node involvement, as well as disease-free survival (DFS) and overall survival (OS), between infiltrating ductal carcinoma with (group 1) and without (group 2) intraductal carcinoma component in order to determine the prognostic value of the intraductal component.

Methods

Data from 389 cases of infiltrating ductal carcinoma of the breast were included in the study by means of reviewing medical charts and pathology slides.

Results

There was no statistically significant difference between both groups regarding node status. The 5-year DFS rate was 90.7% in group 1 and 81.8% in group 2 (p = 0.014), with a median follow-up of 73.2 months (95% CI 68.3–77.4). There was no statistically significant difference in 5-year OS between groups (98% group 1 vs. 93% group 2) with a median global survival of 134 months (95% CI 131–137).

Conclusions

The presence of intraductal component in the infiltrating carcinoma seems to increase DFS and may be an independent and favorable prognostic factor for breast cancer.

Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Eng J Med. 1985;312:146–51.CrossRef

Dupont WD, Anderson TJ, Rogers LW. Epithelial hyperplasia. In: Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone; 1987. p. 120–56.

Tresserra F, Grasses PJ, Garrido M. Lesiones hiperplásicas y preinvasivas precursoras del cáncer de mama: desde la epiteliosis hasta la neoplasia ductal intraepitelial. Rev Senología Patol Mam. 2006;19:162–4.

Connolly JL, Boyages J, Schnitt SJ, Recht A, Silen W, Sadowsky N, et al. In situ carcinoma of the breast. Annu Rev Med. 1989;40:173–80.CrossRefPubMed

Dundar MM, Badve S, Bilgin G, Raykar V, Jain R, Sertel O, Gurcan MN. Computerized classification of intraductal breast lesions using histopathological images. IEEE Trans Biomed Eng. 2011;58(7):1977–84.CrossRefPubMed

Allred DC. Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr. 2010;2010(41):134–8.CrossRefPubMed

Buerger H, Mommers EC, Littman R, Simon R, Diallo R, Poremba C, et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least 2 different lines of genetic evolution. J Pathol. 2001;194:165–70.CrossRefPubMed

Hwang ES, DeVries S, Chew KL, Moore DH 2nd, Kerlikowske K, Thor A, et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res. 2004;10:5160–7.CrossRefPubMed

Irvine T, Fentiman IS. Biology and a treatment of ductal carcinoma in situ. Expert Rev Anticancer Ther. 2007;7:135–45.CrossRefPubMed

10.

Wiechmann L, Kuerer HM. The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer. 2008;112(10):2130–42.CrossRefPubMed

11.

Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003;5:320–8.

12.

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10.CrossRefPubMed

13.

Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of breast ductal carcinoma in situ. Lancet. 1995;345:1154–7.CrossRefPubMed

14.

Tresserra F, Martínez MA. Factores pronósticos en el cáncer de mama: parte I. Factores morfológicos. Rev Senología Patol Mam. 2008;21:170–4.

15.

O’Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 1998;90:697–703.CrossRefPubMed

16.

Chuaqui RF, Zhuang Z, Emmert-Buck MR, Liotta LA, Merino MJ. Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast. Am J Pathol. 1997;150(1):297–303.PubMed

17.

O’Malley FP, Pinder SE. Breast pathology. 1st ed. Philadelphia: Churchill Livingstone; 2006.

18.

Malafa M, Chaudhuri B, Thomford NR, Chadhuri PK. Estrogen receptors in ductal carcinoma in situ of the breast. Am Surg. 1990;56:436–9.PubMed

19.

Barnes R, Masood S. Potential value of hormone receptor assay in carcinoma in situ of breast. Am J Clin Pathol. 1990;94:533–7.PubMed

20.

Chaudhuri B, Crist KA, Mucci S, Malafa M, Chaudhuri PK. Distribution of estrogen receptor in ductal carcinoma in situ of the breast. Surgery. 1993;113(2):134–7.PubMed

21.

Poller DN, Galea M, Pearson D, Bell J, Gullick WJ, Elston CW, et al. Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma. Breast Cancer Res Treat. 1991;20:3–10.CrossRefPubMed

22.

Visscher DW, Sarkar FH, Crissman JD. Correlation of DNA ploidy with c-erbB-2 expression in preinvasive and invasive breast tumors. Anal Quant Cytol Histol. 1991;13:418–24.PubMed

23.

Lodato RF, Maguire HC Jr, Greene MI, Weiner DB, LiVolsi VA. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol. 1990;3:449–54.PubMed

24.

Allred DC, Mohsin SK. Biological features of premalignant disease in the human breast. J Mammary Gland Biol Neoplasia. 2000;5:351–64.CrossRefPubMed

25.

Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200–6.CrossRefPubMed

26.

Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17–32.CrossRefPubMed

27.

Hu M, Yao J, Cai L, Bachman KE, van den Brule F, Velculescu V, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet. 2005;37:899–905.CrossRefPubMed

Title: Influence of the in situ component in 389 infiltrating ductal breast carcinomas
Authors: Pau Carabias-Meseguer
Ignacio Zapardiel
Maite Cusidó-Gimferrer
Sonia Godoy-Tundidor
Francesc Tresserra-Casas
Ignacio Rodriguez-García
Rafael Fábregas-Xauradó
Jordi Xercavins-Montosa
Publication date: 01-07-2013
Publisher: Springer Japan
Published in: Breast Cancer / Issue 3/2013
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-011-0330-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2013

Phyllodes tumor showing intraductal growth

Identification of candidates for postmastectomy radiotherapy in patients with pT3N0M0 breast cancer

Sentinel lymph node biopsy in patients with breast cancer using superparamagnetic iron oxide and a magnetometer

Measuring of the maximum fat lesion ratio

Autologous fat grafting: an innovative solution for the treatment of post-mastectomy pain syndrome

Impact of aggregate of risk factors for isolated locoregional failure in breast cancer patients treated with mastectomy without radiotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer